Skip to main content
Figure 10 | Journal of Translational Medicine

Figure 10

From: Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

Figure 10

Novel, minimally-invasive clinical assay for cancer detection and monitoring using MDSC biomarkers. A, Schematic showing a novel, minimally-invasive clinical assay for cancer detection and monitoring. Patient peripheral blood cells are analyzed by routine flow cytometry for the presence of myeloid-derived suppressor cells (MDSC) as a marker for tumor presence. Active MDSC are distinguished from normal blood cells by a unique 3-marker phenotype that correlates directly with suppressive function. Accumulation of active MDSC correlates directly with disease stage and tumor burden, allowing physicians to track disease stage, tumor response to therapy, and tumor recurrence or progression by a simple blood test. B, Preliminary data demonstrating the CD33+ MDSC subset in the peripheral blood of head and neck cancer patients using a recently identified phenotype: CD33+HLA-DRlowHIF1α+. Ten milliliters of peripheral blood was collected from normal, healthy volunteers or HNSCC cancer patients under Institutional Review Board-approved studies HS-06-00579 and HS-09-00048. Cells were stained for CD33+ and HLA-DR+ using fluorescence-labeled monoclonal antibodies, then cells were fixed and permeabilized for intracellular staining of HIF1α by a third antibody. Stained sample PBMC and isotype controls were analyzed on a FACSCalibur flow cytometry using CellQuestPro software and collecting 50,000 live leukocyte events. CD33+HLA-DRlowHIF1α+ cells were found to be 15.78-16.23% of myeloid cells in cancer patients compared with 0.12-1.99% in healthy controls.

Back to article page